Why BENLYSTA?

Dr. Elaine Lambert, Rheumatologist

Paid consultant to GSK at the time of filming.

video transcript

DR. LAMBERT: I’m Elaine Lambert, I’m a private practice Rheumatologist in San Mateo, California.

ON-SCREEN TEXT: Dr. Elaine Lambert, Rheumatologist
Paid consultant to GSK at the time of filming.

ON-SCREEN TEXT: “Why BENLYSTA?”
Stay tuned for Important Product Information

DR. LAMBERT: Contributing factors that made my decision very easy to start BENLYSTA were the fact that we had been waiting for so very long for a new agent to come along to treat our patients with lupus,...

ON-SCREEN TEXT: Waiting so long for new agent

DR. LAMBERT: ... and so in 2011 it had been more than 50 years since we had a new drug approved by the FDA. The previous drugs that were grandfathered in were, a glucocorticoid, an antimalarial, and aspirin, and we’d been borrowing immunosuppressive drugs from many different other areas to treat our patients and mostly having to rely on them, and also high doses of glucocorticoids.

DR. LAMBERT: So, to have BENLYSTA come along as a drug that was specifically designed for lupus and it was in a double-blinded, placebo-controlled clinical trial setting that we’d never had data for lupus in the past. So, that made it very easy to say to patients, “I want you to try this new agent.”

ON-SCREEN TEXT: “Specifically designed for lupus”

DR. LAMBERT: And also, the safety profile made me very comfortable to start people on BENLYSTA to help control their lupus.

ON-SCREEN TEXT: Comfortable with safety profile

DR. LAMBERT: Click on the link for more information

ON-SCREEN TEXT: BENLYSTAHCP.com

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ and older with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:

BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK or licensor. BELVID220046 August 2022 Produced in USA.

You may also like

BENLYSTA patient story

Dr. Elaine Lambert, Rheumatologist

Why BENLYSTA?

Dr. Grace Wright, Rheumatologist

Paid consultants to GSK at the time of filming.

Icon: Computer

Join us for a live webinar

Learn more